NEW YORK – CareDx said on Wednesday that it has priced an underwritten public offering of 1,923,077 shares of its common stock, at $91 per share.
The transplant diagnostics company expects gross proceeds from the offering of $175 million. In addition, CareDx has granted the underwriters a 30-day option to purchase up to 288,461 additional shares. In a filing with the US Securities and Exchange Commission, CareDx estimated that the net proceeds from the offering will be approximately $164.1 million, or about $188.8 million if the underwriters exercise their option to purchase the additional shares.
The company said it intends to use the net proceeds for working capital and general corporate purposes. The offering is expected to close on or about Jan. 25.
Goldman Sachs and Jefferies are acting as joint book-running managers for the offering. Raymond James, BTIG, Craig-Hallum Capital Group, and HC Wainwright are acting as co-managers.